You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents

    SBC: Stemsynergy Therapeutic            Topic: 102

    PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an electrical impedance myography (EIM) vaginal device for the evaluation of pelvic skeletal muscles

    SBC: BOLD TYPE LLC            Topic: NICHD

    1 Abstract2 Bold Type is developing the “SenseWand”, a wireless pelvic floor diagnostic system (device and app)3 to evaluate pelvic floor muscle health using electrical impedance myography (EIM). PFDs are complex4 conditions (e.g. pelvic organ prolapse, stress urinary incontinence, high tone pelvic floor dysfunction) that impact5 millions of women worldwide. It is estimated that PFDs will affe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Aim protein-based anti-inflammatory therapeutic for the treatment of IBD

    SBC: Keybiome LLC            Topic: 300

    Inflammatory bowel disease (IBD), which is subdivided into ulcerative colitis (UC) and Crohn’s disease (CD), constitutes a prevalent and growing clinical health problem worldwide. These diseases are characterized by debilitating symptoms including diarrhea, abdominal pain, and fatigue, and increased risk of gastrointestinal cancers. In addition, IBD patients have perturbed intestinal microbiomes ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Practice Wellness: Equipping home visitors with skills in reflective coaching, parent mediated child development, and occupational wellness to strengthen child outcomes among low-resourced families

    SBC: SAAVSUS INC            Topic: NICHD

    The first 3 years of a child’s life are critical in setting the stage for future learning, behavior, and health. Children living in poverty during these formative years are exposed to environments characterized by insufficient human service resources and greater exposure to multiple forms and frequency of adverse events, which can undermine their developmental potential. Home visiting has become ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development and validation of a high-fidelity gynecologic training platform for robotic-assisted surgery using 3D printing technology

    SBC: LAZARUS 3D, INC.            Topic: NIBIB

    ABSTRACT This Phase I Small Business Innovation and Research (SBIR) proposal aims to develop and validate a synthetic Soft-tissue Operative Female Training (SOFT) platform that improves training for complex and high-risk procedures in gynecology. The sedentary lifestyle of Americans is expected to increase the incidence of gynecological pathologies treated surgically, including uterine fibroids (U ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites

    SBC: EMMUNE INC            Topic: R

    We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government